We thank Jaydira Del Rivero, MD, for reviewing this blog post. In March 2025, the U.S. FDA approved a new treatment option for neuroendocrine tumors: cabozantinib. (Cabometyx® is the brand name of this medication, manufactured by Exelixis.) Although this pill has long been used to treat other cancers, it is now approved for patients 12 years and older with previously treated, advanced neuroendocrine tumors. 👉 For background on the CABINET trial and what the trial data showed, read our March...